- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Interventions
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 4
- States / cities
- Davis, California • Duarte, California • South Pasadena, California + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 3,622
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Paclitaxel poliglumex, Carboplatin, External beam radiation therapy
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 8
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
- Conditions
- Advanced Cancer, Non-Small Cell Lung Cancer
- Interventions
- MKC-1, pemetrexed
- Drug
- Lead sponsor
- CASI pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Iowa City, Iowa • Seattle, Washington + 1 more
- Conditions
- Lung Cancer
- Interventions
- immunohistochemistry staining method, biopsy, surgery
- Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 56
- States / cities
- Mobile, Alabama • Los Angeles, California • Pasadena, California + 37 more
- Conditions
- Lung Cancer, Nonsmall Cell
- Interventions
- Crizotinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
- Interventions
- Tepotinib
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • Encinitas, California • Orange, California + 30 more
- Conditions
- Lung Cancer
- Interventions
- lobectomy, segmentectomy or wedge resection
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 373
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 245 more
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
- Interventions
- SKB264
- Drug
- Lead sponsor
- Klus Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC)
- Interventions
- Copanlisib, Nivolumab
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Los Angeles, California • Denver, Colorado + 2 more
- Conditions
- Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive
- Interventions
- Ensartinib
- Drug
- Lead sponsor
- Xcovery Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 4
- States / cities
- Stanford, California • Bethesda, Maryland • Nashville, Tennessee + 1 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Lung Metastasis
- Interventions
- Porfimer sodium, Fiber optic
- Drug · Device
- Lead sponsor
- Concordia Laboratories Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- Gainesville, Florida • Atlanta, Georgia • Elk Grove Village, Illinois + 3 more
- Conditions
- Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer, Pulmonary Disease, Chronic Obstructive
- Interventions
- LIFE Bronchoscopy
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
- Interventions
- NT-175
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 15
- States / cities
- Duarte, California • Palo Alto, California • Sacramento, California + 7 more
- Conditions
- Rash, Non-small-Cell Lung Cancer
- Interventions
- ACZONE (dapsone) Gel, 5%, Vehicle Control
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Hershey, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Adenocarcinoma, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Triple Negative Breast Cancer
- Interventions
- BL-B01D1
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 22
- States / cities
- Beverly Hills, California • Duarte, California • Orange, California + 17 more
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- Motexafin gadolinium and pemetrexed
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 11
- States / cities
- Huntington Beach, California • Long Beach, California • Chicago, Illinois + 8 more
- Conditions
- Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
- Interventions
- ADV/HSV-tk, Valacyclovir, SBRT, Pembrolizumab
- Biological · Drug · Radiation
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Photon Therapy, Proton Therapy, Paclitaxel, Carboplatin
- Radiation · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- pyrazoloacridine
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy
- Radiation · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Cemiplimab, Platinum based chemotherapy, Stereotactic body radiation therapy
- Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stage III Non-small Cell Lung Cancer, Unresectable
- Interventions
- Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 28
- States / cities
- Anaheim, California • Duarte, California • Sacramento, California + 24 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort)
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 80
- States / cities
- Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more